Two Sigma Advisers’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Two Sigma Advisers’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-33,600	Closed	-$337K	–	2700
2023 Q4	$337K	Buy	+33,600	New	+$152K	﹤0.01%	2070

Two Sigma Advisers's GRCL Position: Q1 2024 in Review

Two Sigma Advisers sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 33,600 shares — an estimated $337K sold.

Two Sigma Advisers first reported a position in GRCL in Q4 2023 and held it in 1 quarter. The position peaked at $337K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Two Sigma Advisers reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Two Sigma Advisers sold 33,600 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $337K.
Two Sigma Advisers first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2023 and held it in 1 quarter.
Two Sigma Advisers's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $337K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Two Sigma Advisers's 13F filing for Q1 2024, filed 15 May 2024.